<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00734292</url>
  </required_header>
  <id_info>
    <org_study_id>SKY2028-2-002</org_study_id>
    <nct_id>NCT00734292</nct_id>
  </id_info>
  <brief_title>Single-dose Crossover Study to Evaluate the Early Bronchodilating Effect of FlutiForm HFA pMDI in Adult Subjects With Mild to Moderate Asthma</brief_title>
  <official_title>A Randomized, Placebo-controlled, Double-blind, Crossover, Single-dose Exposure Study to Evaluate the Early Bronchodilating Effect of FlutiForm 100/10 µg HFA pMDI and FlutiForm 250/10 µg HFA pMDI, Compared to Placebo in Adult Subjects With Mild to Moderate Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SkyePharma AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>SkyePharma AG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to evaluate the early bronchodilating effect of SKP
      FlutiForm HFA pMDI compared to placebo.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">October 2008</completion_date>
  <primary_completion_date type="Actual">September 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline FEV1 to post study drug dosing FEV1</measure>
    <time_frame>3 minutes</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline FEV1 to post study drug dosing FEV1</measure>
    <time_frame>8, 15, 30, and 60 minutes</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">39</enrollment>
  <condition>Mild to Moderate Asthma</condition>
  <arm_group>
    <arm_group_label>I</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Period 1 Treatment Regimen A: FlutiForm 250/10 ug
Period 2 Treatment Regimen B: FlutiForm 100/10 ug
Period 3 Treatment Regimen C: placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>II</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Period 1 Treatment Regimen B: FlutiForm 100/10 ug
Period 2 Treatment Regimen C: placebo
Period 3 Treatment Regimen A: FlutiForm 250/10 ug</description>
  </arm_group>
  <arm_group>
    <arm_group_label>III</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Period 1 Treatment Regimen C: placebo
Period 2 Treatment Regimen A: FlutiForm 250/10 ug
Period 3 Treatment Regimen B: FlutiForm 100/10 ug</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluticasone propionate, formoterol fumarate</intervention_name>
    <description>● Period 1 Treatment Regimen A: FlutiForm 250/10 ug
FlutiForm HFA pMDI (250/10 ug); (two actuations of FlutiForm HFA pMDI 125/5 ug/actuation)
● Period 2 Treatment Regimen B: FlutiForm 100/10 ug
FlutiForm HFA pMDI (100/10 ug); (two actuations of FlutiForm HFA pMDI 50/5 ug/actuation)
● Period 3 Treatment Regimen C: placebo
SKP placebo; (two actuations)</description>
    <arm_group_label>I</arm_group_label>
    <other_name>FlutiForm</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>fluticasone propionate, formoterol fumarate</intervention_name>
    <description>● Period 1 Treatment Regimen B: FlutiForm 100/10 ug
FlutiForm HFA pMDI (100/10 ug); (two actuations of FlutiForm HFA pMDI 50/5 ug/actuation)
● Period 2 Treatment Regimen C: placebo
SKP placebo; (two actuations)
● Period 3 Treatment Regimen A: FlutiForm 250/10 ug
FlutiForm HFA pMDI (250/10 ug); (two actuations of FlutiForm HFA pMDI 125/5 ug/actuation)</description>
    <arm_group_label>II</arm_group_label>
    <other_name>FlutiForm</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>fluticasone propionate, formoterol fumarate</intervention_name>
    <description>● Period 1 Treatment Regimen C: placebo
SKP placebo; (two actuations)
● Period 2 Treatment Regimen A: FlutiForm 250/10 ug
FlutiForm HFA pMDI (250/10 ug); (two actuations of FlutiForm HFA pMDI 125/5 ug/actuation)
● Period 3 Treatment Regimen B: FlutiForm 100/10 ug
FlutiForm HFA pMDI (100/10 ug); (two actuations of FlutiForm HFA pMDI 50/5 ug/actuation)</description>
    <arm_group_label>III</arm_group_label>
    <other_name>FlutiForm</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects with documented history of mild to moderate asthma currently taking a stable
             dose of inhaled corticosteroid

        Exclusion Criteria:

          -  Participation in a prior FlutiForm study

          -  Smoking history within the last 12 months,

          -  Significant, non-reversible, pulmonary disease

          -  Life-threatening asthma within the last year
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Mission Viejo</city>
        <state>California</state>
        <zip>92691</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Valrico</city>
        <state>Florida</state>
        <zip>33594</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Medford</city>
        <state>Oregon</state>
        <zip>97504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>West Allis</city>
        <state>Wisconsin</state>
        <zip>53227</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 4, 2008</study_first_submitted>
  <study_first_submitted_qc>August 13, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 14, 2008</study_first_posted>
  <disposition_first_submitted>August 24, 2010</disposition_first_submitted>
  <disposition_first_submitted_qc>August 24, 2010</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">August 27, 2010</disposition_first_posted>
  <last_update_submitted>August 24, 2010</last_update_submitted>
  <last_update_submitted_qc>August 24, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 27, 2010</last_update_posted>
  <responsible_party>
    <name_title>SkyePharma AG</name_title>
    <organization>SkyePharma AG</organization>
  </responsible_party>
  <keyword>Asthma</keyword>
  <keyword>Asthma Mild to Moderate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluticasone</mesh_term>
    <mesh_term>Formoterol Fumarate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

